NOL3 is a predictor of patient outcome

摘要

The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

主权项

1. A method of treating a subject having cancer, the method comprising
administering a therapeutically effect amount of an IAP inhibitor to the subject having cancer when the level of NOL3 expression measured in a cancer cell-containing sample from the subject having cancer is lower than a reference level of NOL3 expression measured in a sample from a subject without the cancer; wherein the IAP inhibitor is a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1 is H or C1C4 alkyl; R2 is H or C1C4-alkyl; R3 is H or C1C4 alkyl; A is 5- or 6-membered heteroaryl containing 1-4 ring heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, the heteroaryl being unsubstituted or substituted with lower alkyl, amino, or halo; D is O, C(O), or NCH3; A1 is phenyl or 5- or 6-membered heteroaryl containing 1-4 ring heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, the phenyl and the heteroaryl being unsubstituted or substituted with halogen; M is H; and n is 0.